text: Mass Spectrometry based Proteomics and Glycoproteomics in COVID 19 Biomarkers Identification A Mini review The first corona pandemic coronavirus disease 2019 COVID 19 caused a huge health crisis and incalculable damage worldwide Knowledge of how to cure the disease is urgently needed Emerging immune escaping mutants of the virus suggested that it may be potentially persistent in human society as a regular health threat as the flu virus Therefore it is imperative to identify appropriate biomarkers to indicate pathological and physiological states and more importantly clinic outcomes Proteins are the performers of life functions and their abundance and modification status can directly reflect the immune status Protein glycosylation serves a great impact in modulating protein function The use of both unmodified and glycosylated proteins as biomarkers has also been proved feasible in the studies of SARS Zika virus influenza etc In recent years mass spectrometry based glycoproteomics as well as proteomics approaches advanced significantly due to the evolution of mass spectrometry We focus on the current development of the mass spectrometry based strategy for COVID 19 biomarkers investigation Potential application of glycoproteomics approaches and challenges in biomarkers identification are also discussed 